Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus DM02
- Development stage
- Unknown
- Lead developer
- The First Affiliated Hospital of Harbin Medical University
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus DM02 is a probiotic strain being investigated for its potential renal protective effects in patients with stage 3–5 chronic kidney disease (CKD). Developed by The First Affiliated Hospital of Harbin Medical University, the therapy aims to modulate the gut-kidney axis by reducing the abundance of pathogenic gut bacteria, specifically Escherichia coli. By altering the gut microbiota composition, DM02 is intended to decrease the production and circulating levels of uremic toxins like indoxyl sulfate, which are known to contribute to CKD progression and cardiovascular complications. It is currently being evaluated in a Phase 0 clinical trial in China to assess its impact on the gut microbiome and clinical outcomes in CKD patients.
- Other names
- Lactobacillus reuteri DM02
Beyond the preview
Go deeper on Lactobacillus rhamnosus DM02.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus DM02.